文献速递肿瘤 PET/CT核素与放射性配体治疗

一种标记氟-18和镥-177的放射性杂合诊疗配体用于成纤维细胞活化蛋白靶向成像与放射性核素治疗

A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-03-03

本研究开发了含有机硅基氟受体(SiFA)和DOTAGA螯合剂的FAP靶向配体LuFL,可分别用氟-18和镥-177标记。细胞实验显示LuFL对FAP的亲和力优于FAPI-04,[18F]/[177Lu]标记物在HT-1080-FAP荷瘤裸鼠中肿瘤摄取更高、滞留更久,[177Lu]Lu-LuFL抑瘤效果显著优于对照组和[177Lu]Lu-FAPI-04组。

要点

  • LuFL对FAP的IC50为2.29±1.12 nM,[natLu]Lu-LuFL为2.53±1.87 nM,均优于FAPI-04的6.69±0.88 nM。
  • [18F]/[177Lu]标记的LuFL在HT-1080-FAP荷瘤裸鼠中肿瘤摄取高于[68Ga]/[177Lu]Ga/Lu-FAPI-04,且肿瘤滞留更久。
  • [177Lu]Lu-LuFL对肿瘤生长的抑制显著优于对照组和[177Lu]Lu-FAPI-04组。

核心结论

  • 含SiFA和DOTAGA的新型FAP靶向放射性药物LuFL标记过程简单短时,相比FAPI-04具有更高的细胞摄取、更好的FAP结合亲和力、更高的肿瘤摄取和更长的滞留。
  • 氟-18和镥-177标记的LuFL初步实验显示有前景的肿瘤成像特性和良好的抗肿瘤疗效。

研究设计与样本

  • 合成前体LuFL(20)和[natLu]Lu-LuFL(21),并用氟-18和镥-177进行标记。
  • 进行一系列细胞实验表征结合亲和力和FAP特异性。
  • 在HT-1080-FAP荷瘤裸鼠中进行PET成像、SPECT成像和生物分布研究评估药代动力学。
  • 在HT-1080-FAP异种移植瘤中比较[177Lu]Lu-LuFL([177Lu]21)与[177Lu]Lu-FAPI-04的抗肿瘤疗效。

主要发现

  • LuFL(20)和[natLu]Lu-LuFL(21)对FAP的IC50分别为2.29±1.12 nM和2.53±1.87 nM,FAPI-04为6.69±0.88 nM。
  • 18F-/177Lu标记的21在HT-1080-FAP细胞中显示高特异性摄取和内化。
  • [18F]/[177Lu]21的micro-PET、SPECT成像和生物分布研究显示肿瘤摄取高于[68Ga]/[177Lu]Ga/Lu-FAPI-04,肿瘤滞留更长。
  • 放射性核素治疗研究中,[177Lu]21组对肿瘤生长的抑制显著大于对照组和[177Lu]Lu-FAPI-04组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A series of radiotracers targeting fibroblast activation protein (FAP) with great pharmacokinetics have been developed for cancer diagnosis and therapy. Nevertheless, the use of dominant PET tracers, gallium-68-labeled FAPI derivatives, was limited by the short nuclide half-life and production scale, and the therapeutic tracers exhibited rapid clearance and insufficient tumor retention. In this study, we developed a FAP targeting ligand, LuFL, containing organosilicon-based fluoride acceptor (SiFA) and DOTAGA chelator, capable of labeling fluorine-18 and lutetium-177 in one molecular with simple and highly efficient labeling procedure, to achieve cancer theranostics. METHODS: The precursor LuFL (20) and [natLu]Lu-LuFL (21) were successfully synthesized and labeled with fluorine-18 and lutetium-177 using a simple procedure. A series of cellular assays were performed to characterize the binding affinity and FAP specificity. PET imaging, SPECT imaging, and biodistribution studies were conducted to evaluate pharmacokinetics in HT-1080-FAP tumor-bearing nude mice. A comparison study of [177Lu]Lu-LuFL ([177Lu]21) and [177Lu]Lu-FAPI-04 was carried out in HT-1080-FAP xenografts to determine the cancer therapeutic efficacy. RESULTS: LuFL (20) and [natLu]Lu-LuFL (21) demonstrated excellent binding affinity towards FAP (IC50: 2.29 ± 1.12 nM and 2.53 ± 1.87 nM), compared to that of FAPI-04 (IC50: 6.69 ± 0.88 nM). In vitro cellular studies showed that 18F-/177Lu-labeled 21 displayed high specific uptake and internalization in HT-1080-FAP cells. Micro-PET, SPECT imaging and biodistribution studies with [18F]/[177Lu]21 revealed higher tumor uptake and longer tumor retention than those of [68 Ga]/[177Lu]Ga/Lu-FAPI-04. The radionuclide therapy studies showed significantly greater inhibition of tumor growth for the [177Lu]21 group, than for the control group and the [177Lu]Lu-FAPI-04 group. CONCLUSION: The novel FAPI-based radiotracer containing SiFA and DOTAGA was developed as a theranostics radiopharmaceutical with simple and short labeling process, and showed promising properties including higher cellular uptake, better FAP binding affinity, higher tumor uptake and prolong retention compared to FAPI-04. Preliminary experiments with 18F- and 177Lu-labeled 21 showed promising tumor imaging properties and favorable anti-tumor efficacy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Yang T, Peng L, Qiu J, et al. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy. Eur J Nucl Med Mol Imaging. 2023. PMID: 36864362. doi:10.1007/s00259-023-06169-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。